In silico analysis of potential human T Cell antigens from Mycobacterium tuberculosis for the development of subunit vaccines against tuberculosis

References

• AndradeJr DR, Santos SA, Castro I, Andrade DR. (2008). Correlation between serum tumor necrosis factor alpha levels and clinical severity of tuberculosis. Brazil J Infect Dis, 12, 226–33
   Google Scholar
• Brennan MJ, Fruth U, Milstien J, et al. (2007). Development of new tuberculosis vaccines: A global perspective on regulatory issues. PLoS Med, 4, e252
   PubMed Web of Science ®Google Scholar
• Bui HH, Sidney J, Peters B, et al. (2005). Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics, 57, 304–14
   PubMed Web of Science ®Google Scholar
• Coler RN, Dillon DC, Skeiky YA, et al. (2009). Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning. Vaccine, 27, 223–33
   Google Scholar
• Deenadayalan A, Heaslip D, Rajendiran AA, et al. (2010). Immunoproteomic identification of human T cell antigens of Mycobacterium tuberculosis that differentiate healthy contacts from tuberculosis patients. Mol Cell Proteomics, 9, 538–49
   Google Scholar
• Dey B, Jain R, Gupta UD, et al. (2011). A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis. PLoS One, 6, e23360
   PubMed Web of Science ®Google Scholar
• Dissel JT, Soonawala D, Joosten SA, et al. (2011). Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine, 29, 2100–9
   Google Scholar
• Flower DR. (2008). Vaccines: Data Driven Prediction of Binders, Epitopes and Immunogenicity in Bioinformatics for Vaccinology. Oxford, UK: Wiley-Blackwell, 167–216
   Google Scholar
• Gomase VS, Chitlange NR. (2010). Immunoproteomics approach for development of MHC binders and fragment based peptide vaccines from Treponema pallidum. J Biosci Technol, 1, 84–9
   Google Scholar
• Grotzke JE, Lewinsohn DM. (2005). Role of CD8+ T lymphocytes in control of Mycobacterium tuberculosis infection. Microbes Infect, 7, 776–88
   Google Scholar
• Hanif SN, El-Shammy AM, Al-Attiyah R, Mustafa AS. (2008). Whole blood assays to identify Th1 cell antigens and peptides encoded by Mycobacterium tuberculosis-specific RD1 genes. Medical Prin Pract: Inter J Kuwait Univ Health Sci Centre, 17, 244–9
   Google Scholar
• Harari A, Rozot V, Enders FB, et al. (2011). Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nature Med, 17, 372–6
   PubMed Web of Science ®Google Scholar
• Kao FF, Mahmuda S, Pinto R, et al. (2012). The secreted lipoprotein, MPT83, of Mycobacterium tuberculosis is recognized during human tuberculosis and stimulates protective immunity in mice. PLoS One, 7, e34991
   PubMedGoogle Scholar
• Kimman TG, Vandebriel RJ, Hoebee B. (2007). Genetic variation in the response to vaccination. Commun Genet, 10, 201–17
   PubMedGoogle Scholar
• Kumar M, Meenakshi N, Sundaramurthi JC, et al. (2010). Immune response to Mycobacterium tuberculosis specific antigen ESAT-6 among south Indians. Tuberculosis (Edinb), 90, 60–9
   Google Scholar
• Kumar M, Raja A. (2010). Cytotoxicity responses to selected ESAT-6 and CFP-10 peptides in Tuberculosis. Cellular Immunology, 265, 146–55
   Google Scholar
• Kunst H. (2006). Diagnosis of latent tuberculosis infection: The potential role of new technologies. Respir Med, 100, 2098–106
   Google Scholar
• Lahey T, Sheth S, Matee M, et al. (2010). Interferon gamma responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis. J Infect Dis, 202, 1265–72
   Google Scholar
• Law K, Weiden M, Harkin T, et al. (1996). Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. Amer J Respir Crit Care Med, 153, 799–804
   PubMed Web of Science ®Google Scholar
• Lu J, Wang C, Zhou Z, et al. (2011). Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein. Clin Develop Immunol, Epub 2011
   Google Scholar
• McShane H, Pathan AA, Sander CR, et al. (2005). Boosting BCG with MVA85A: The first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis, 85, 47–52
   PubMed Web of Science ®Google Scholar
• Mori T, Sakatani M, Yamagishi F, et al. (2004). Specific detection of tuberculosis infection: An interferon-γ-based assay using new antigens. Amer J Respir Crit Care Med, 170, 59–64
   PubMed Web of Science ®Google Scholar
• Mustafa AS, Shaban FA. (2006). ProPred analysis and experimental evaluation of promiscuous T-cell epitopes of three major secreted antigens of Mycobacterium tuberculosis. Tuberculosis (Edinb), 86, 115–24
   PubMed Web of Science ®Google Scholar
• Nielsen M, Lundegaard C, Worning P, et al. (2003). Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci, 12, 1007–17
   PubMed Web of Science ®Google Scholar
• Noguchi H, Kato R, Hanai T, et al. (2002). Hidden Markov model-based prediction of antigenic peptides that interact with MHC class II molecules. J Biosci Bioeng, 94, 264–70
   PubMed Web of Science ®Google Scholar
• Oftung F, Lundin KEA, Geluk A, et al. (1997). Primary structure and MHC restriction of peptide defined T-cell epitopes from recombinantly expressed mycobacterial protein antigens. Med Princ Pract, 6, 66–73
   Google Scholar
• Olsen AW, Hansen PR, Holm A, Andersen P. (2000). Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Euro J Immunol, 30, 1724–32
   PubMed Web of Science ®Google Scholar
• Pal PG, Horwitz MA. (1992). Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun, 60, 4781–92
   PubMed Web of Science ®Google Scholar
• Palma C, Iona E, Giannoni F, et al. (2007). The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice. Cell Microbiol, 9, 1455–65
   Google Scholar
• Raghavan S, Selvaraj P, Swaminathan S, et al. (2009). Haplotype analysis of HLA-A, -B antigens and -DRB1 alleles in south Indian HIV-1-infected patients with and without pulmonary tuberculosis. Int J Immunogenet, 36, 129–33
   Google Scholar
• Sable SB, Verma I, Behera D, et al. (2005). Human immune recognition-based multicomponent subunit vaccines against tuberculosis. Eur Respir J, 25, 902–10
   Google Scholar
• Sampaio LH, Stefani MM, Oliveira RM, et al. (2011). Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development. BMC Infect Dis, 11, 26
   Google Scholar
• Schluger NW, Rom WN. (1998). The host immune response to tuberculosis. Am J Respir Crit Care Med, 157, 679–69
   PubMed Web of Science ®Google Scholar
• Scholvinck E, Wilkinson KA, Whelan AO, et al. (2004). Gamma interferon-based immunodiagnosis of tuberculosis: Comparison between whole-blood and enzyme-linked immunospot methods. J Clin Microbiol, 42, 829–83
   Google Scholar
• Sikora A, Kozioł-Montewka M, Książek A, et al. (2013). Assessment of cytokine release after in vitro stimulation of whole blood with legionella pneumophila in immunocompromised patients. Immunol Invest, 42, 1–17
   Web of Science ®Google Scholar
• Singh H, Raghava GP. (2001). ProPred: Prediction of HLA-DR binding sites. Bioinformatics, 17, 1236–7
   PubMed Web of Science ®Google Scholar
• Sundaramurthi JC, Brindha S, Shobitha SR, et al. (2012). In silico identification of potential antigenic proteins and promiscuous CTL epitopes in Mycobacterium tuberculosis. Infect Genet Evol, 12, 1312–8
   PubMed Web of Science ®Google Scholar
• Takenami I, Loureiro C, Machado Jr A, et al. (2013). Blood cells and interferon-gamma levels correlation in latent tuberculosis infection. ISRN Pulmonol, 2013, 1--8
   Google Scholar
• Talreja J, Bhatnagar A, Jindal SK, et al. (2003). Influence of Mycobacterium tuberculosis on differential activation of helper T-cells. Clin Exp Immunol, 131, 292–8
   Google Scholar
• Torres M, Herrera T, Villareal H, et al. (1998). Cytokine profiles for peripheral blood lymphocytes from patients with active pulmonary tuberculosis and healthy household contacts in response to the 30-kilodalton antigen of Mycobacterium tuberculosis. Infect Immun, 66, 176–80
   PubMed Web of Science ®Google Scholar
• Vijaya Lakshmi V, Mustafa MI, Santhosh A, et al. (2005). Frequencies of HLA-A, -B, -Dr and -DQ phenotypes in the United Arab Emirates population. Tissue Antigens 66, 107 (Errata. Tissue Antigens 66 (4), 341–341
   Google Scholar
• Vijaya Lakshmi V, Rakh SS, Anu Radha B, et al. (2006). Role of HLA-B51 and HLA-B52 in susceptibility to pulmonary tuberculosis. Infect Genet Evol, 6, 436–9
   Google Scholar
• Weir RE, Morgan AR, Britton WJ, et al. (1994). Development of whole blood assay to measure T cell responses to leprosy: A new tool for immunoepidemiological field studies of leprosy immunity. J Immunol Meth, 176, 93–101
   PubMedGoogle Scholar
• World Health Organization (2012) WHO Global tuberculosis control 2012. Available from: http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf
   Google Scholar
• Zhang GL, Khan AM, Srinivasan KN, et al. (2005). MULTIPRED: A computational system for prediction of promiscuous HLA binding peptides. Nucl Acids Res, 33, W172–9
   PubMed Web of Science ®Google Scholar
• Zvi A, Ariel N, Fulkerson J, et al. (2008). Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses. BMC Med Genom, 1, 18
   PubMed Web of Science ®Google Scholar